Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines
- PMID: 7479384
- DOI: 10.1002/pros.2990270402
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines
Abstract
Baseline cellular plasminogen activator (PA) activity, and the cellular proteins responsible for variations in PA activity were evaluated in three human prostate carcinoma cell lines. Net PA activity in the cell lines PC-3, DU-145, and LNCaP was measured using a plasminogen-dependent fibrin lysis assay. These three cell lines were then analyzed to determine the specific protein(s) responsible for differences in PA activity. mRNA and protein levels of cellular urinary PA (uPA), tissue PA (tPA), PA inhibitor 1 (PAI1), PA inhibitor 2 (PAI2), and uPA receptor (uPAr) were measured using Northern analysis and ELISA assays. Net cellular PA activity in the three cell lines varied over a 3-fold range (PC3 > DU145 >> LNCaP). Net PA activity in the fibrinolysis assay demonstrated a direct correlation with mRNA transcript levels of uPA, tPA, PAI1, and uPAr (PC-3 > DU-145 > LNCaP). uPA protein was identified in both the PC-3 and the DU-145 lines. tPA, PAI1, and PAI2 proteins were identified only in PC-3 cells. In general, cellular protein levels correlated with mRNA levels. These findings demonstrate that prostate carcinoma cell lines vary in their net PA activity. This variability results from both qualitative and quantitative differences in the cellular expression of PA regulatory proteins.
Similar articles
-
Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.Prostate. 1997 Aug 1;32(3):196-204. doi: 10.1002/(sici)1097-0045(19970801)32:3<196::aid-pros6>3.0.co;2-j. Prostate. 1997. PMID: 9254899
-
Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines.J Urol. 1994 Jun;151(6):1691-6. doi: 10.1016/s0022-5347(17)35346-6. J Urol. 1994. PMID: 8189598
-
Plasminogen activators and inhibitors are transcribed during early macaque implantation.Placenta. 2001 Feb-Mar;22(2-3):186-99. doi: 10.1053/plac.2000.0607. Placenta. 2001. PMID: 11170823
-
Regulation and interactions in the activation of cell-associated plasminogen.Cell Mol Life Sci. 2004 Nov;61(22):2840-58. doi: 10.1007/s00018-004-4230-9. Cell Mol Life Sci. 2004. PMID: 15558213 Free PMC article. Review.
-
The plasminogen activator system: biology and regulation.Cell Mol Life Sci. 1999 Oct 1;56(1-2):104-32. doi: 10.1007/pl00000615. Cell Mol Life Sci. 1999. PMID: 11213252 Free PMC article. Review.
Cited by
-
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.Exp Cell Res. 2004 Apr 1;294(2):550-8. doi: 10.1016/j.yexcr.2003.11.023. Exp Cell Res. 2004. PMID: 15023541 Free PMC article.
-
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.Clin Exp Metastasis. 1998 Aug;16(6):513-28. doi: 10.1023/a:1006590217724. Clin Exp Metastasis. 1998. PMID: 9872599
-
Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells.BMC Genomics. 2007 Sep 11;8:318. doi: 10.1186/1471-2164-8-318. BMC Genomics. 2007. PMID: 17845732 Free PMC article.
-
The loss of TGF-beta signaling promotes prostate cancer metastasis.Neoplasia. 2003 May-Jun;5(3):267-77. doi: 10.1016/S1476-5586(03)80058-1. Neoplasia. 2003. PMID: 12869309 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous